TIDMTILS
RNS Number : 4306L
Tiziana Life Sciences PLC
19 July 2017
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences Announces Initiation of a Phase IIa
Clinical Trial with Milciclib in Patients with Hepatocellular
Carcinoma
Milciclib, a novel inhibitor of pan-CDKs, has shown clinical
responses in
refractory cancer patients
London, 19 July, 2017 - Tiziana Life Sciences plc (AIM: TILS), a
clinical stage biotechnology company developing targeted drugs for
cancer and inflammatory diseases, today announces the enrolment of
the first patient in its phase IIa clinical trial with milciclib, a
novel inhibitor of cyclin-dependent kinases (CDKs), in patients
with refractory hepatocellular carcinoma ("HCC"). Top line data
from this trial, being conducted in Italy, Israel, Greece and
Turkey, is expected in Q4 2018. The primary objective of this
multi-centre, multi-country and dose-ranging phase IIa clinical
study is to evaluate the safety of milciclib in HCC patients who
fail to respond to or are intolerant to the existing standard of
care treatment. Subsequently, a phase IIb is planned with the
combination of milciclib with the standard of care treatment
sorafenib in HCC patients.
Milciclib is an inhibitor of several cyclin-dependent kinases
(CDKs), which are commonly overexpressed in tumours resistant to
chemotherapy. Accordingly, the investigational therapy will be
tested in patients who have failed to respond to the standard of
care treatment, sorafenib (NexavarÃ’). Preclinical studies conducted
strongly suggest that milciclib acts primarily through
downregulation of microRNA (miR) 221 and 222, which are known to be
associated with hepatocarcinogenesis and overexpression of these
miRs is also believed to be associated with development of
resistance to sorafenib in HCC patients.
In previous phase I clinical studies, oral treatment with
milciclib was found to be safe and well-tolerated in patients with
advanced solid tumours such as thymoma and thymic carcinoma,
pancreatic carcinoma and colon cancer.(1) The combination of
milciclib with gemcitabine, a well-known nucleoside analogue, in a
phase I dose-escalation study showed favourable clinical responses
in approximately 36% of patients with advanced/metastatic tumours,
including patients previously considered to be resistant to
gemcitabine.(2)
Gabriele Cerrone, Chairman of Tiziana Life Sciences, commented:
"HCC is a real unmet medical need due to its growing incidence and
lack of effective therapy. It is the fifth most common cancer
worldwide and the second most common cause of death from cancer
worldwide."
Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences,
commented: "Oral treatment with milciclib has been well-tolerated
in previous studies with cancer patients. We strongly believe,
based on its unique mechanism of action, that the drug may have
potential to be developed either as a monotherapy or combo-therapy
with sorafenib for treatment of HCC."
Dr. Ilan Yaron, Director of the Department of Medicine at Hebrew
University Hadassah Medical Center, Israel and Chief Medical
Officer of Tiziana Life Sciences, added: "The prognosis for liver
cancer is very poor due to lack of effective therapy. We believe
that milciclib holds promise as an effective anti-cancer treatment
with a high safety profile."
About HCC
Hepatocellular carcinoma is the fifth most common cancer in men
and the ninth in women. Additionally, it is the fifth most common
cancer worldwide and the second most common cause of death from
cancer worldwide.(3) The tumour is associated with chronic
hepatitis B and chronic hepatitis C infections, as well as with
nonalcoholic steatohepatitis. The prognosis for liver cancer is
very poor due to lack of effective therapy.
About Milciclib
Milciclib (PHA-848125AC) is a small molecule inhibitor of
several cyclin dependent kinases (CDKs) such as CDK1, CDK4, CDK5
and CDK7. CDKs are serine threonine kinases that play crucial roles
in progression of the cell cycle from G(1) to S phase.
Overexpression of CDKs and other downstream signalling pathways
that regulate cell cycles have been frequently found to be
associated with development of resistance towards chemotherapies.
Oral treatment with milciclib was found to be effective in reducing
tumour growth in animal models of HCC, possibly through
downregulation of miR-221 and miR-222. In a phase I study, oral
treatment with milciclib was found to be well-tolerated and the
drug showed promising clinical responses in patients with advanced
solid malignancies such as in thymic carcinoma, pancreatic
carcinoma and colon cancer.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules that
treat human disease in oncology and immunology. The Company is
focused on its lead compound milciclib. The Company is also in
clinical development of foralumab. Foralumab is the only fully
human engineered anti-human CD3 antibody in clinical development.
This phase II compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBS),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
inflammatory bowel disease (IBD), psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
Cited References
1. Weiss GJ, Hidalgo M, Borad MJ, et al. (2012) Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs 30:2334-43. doi: 10.1007/s10637-011-9774-6.
2. Aspeslagh, S., Shailubhai, K., Bahleda, R. et al. Cancer Chemother Pharmacol (2017). Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 79:1257-1265.
3. Sahil Mittal and Hashem B. El-Serag (2013) Epidemiology of
HCC: Consider the Population. J Clin Gastroenterol. 2013 Jul;
47(0): S2-S6.
For more information go to
http://www.tizianalifesciences.com
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Contacts
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray +44 (0)20 7213 0883
Beaufort Securities Limited (Broker)
Saif Janjua +44 (0)20 7382 8300
FTI Consulting
Simon Conway / Natalie Garland-Collins +44 (0)20 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAPRPMFTMBMBBIR
(END) Dow Jones Newswires
July 19, 2017 02:00 ET (06:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024